Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664951 | 0.93 | MAPT (0.40) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL7011227 | 0.87 | MAPT (0.44) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL263120 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL10773784 | 0.85 | NPSR1 (0.40) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL263121 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL10542765 | 0.84 | MEN1 (0.40) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL10473858 | 0.84 | MEN1 (0.40) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL5525147 | 0.84 | NPSR1 (0.40) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL10692113 | 0.83 | MAPT (0.41) | CYP1A2CYP2C19MAPTNPSR1LMNA | |
| SCHEMBL10780740 | 0.83 | LMNA (0.37) | CYP1A2CYP2C19MAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | claimed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1995240-B1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-0303291-B1 | Fluorinated benzoyl compounds | ASAHI GLASS CO LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| US-5093515-A | Intermediate for quinolone carboxylic acid bactericide | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| US-4994610-A | Process for preparing fluorinated benzoyl compounds | ASAHI GLASS COMPANY, LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CYP1A2 1317/4885CYP2C19 153/4885MAPT 4880/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | CYP1A2 2147/4885CYP2C19 281/4885MAPT 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.